From ergot fungus to Bicycle Day
Albert Hofmann first synthesized LSD-25 (lysergic acid diethylamide) at Sandoz Laboratories while investigating compounds derived from ergot, a fungus that grows on rye. On April 16, 1943, he accidentally absorbed a small amount and experienced its effects for the first time; three days later, on April 19, he deliberately took what he assumed was a cautious dose — 250 micrograms, which turned out to be several times a typical active dose — and rode his bicycle home through what became a famously overwhelming experience. April 19 is still informally celebrated by psychedelic researchers and enthusiasts as "Bicycle Day."
Psychiatric tool, then countercultural symbol, then Schedule I
Through the 1950s and into the mid-1960s, LSD was legally available and used in serious psychiatric research — Canadian researchers pioneered "psychedelic therapy" for chronic alcoholism, giving patients a single large dose in a supported, prepared setting, and thousands of patients worldwide were treated across various trials during this period (methodologically weaker than what modern trials require, but a real and active field, not fringe). Popularity shifted sharply in the 1960s as LSD moved from clinics into the counterculture — Harvard psychologists Timothy Leary and Richard Alpert became its most visible public advocates, and it became entangled with the era's music, politics, and radical social questioning. That visibility provoked a backlash: the Controlled Substances Act of 1970 placed LSD in the most restrictive category, Schedule I, alongside heroin — legally asserting it has no accepted medical use and a high potential for abuse — which shut down virtually all legitimate research for roughly three decades.
What it actually does, and the real dangers
LSD is not physically addictive in the way opioids, alcohol, or nicotine are — there's no withdrawal syndrome, and tolerance builds so fast with repeated daily use that the drug becomes rapidly less effective, which naturally discourages compulsive use. It also has an extremely wide margin between an active dose and a physically lethal one; there is no well-documented case of a fatal LSD overdose from the drug's direct physiological toxicity alone. That doesn't make it safe. The real dangers are psychological and situational, not toxicological:
Duration and unpredictability. A typical trip lasts 8–12 hours — far longer than most other psychedelics — during which judgment, risk perception, and reality-testing are all significantly altered. Most LSD-related injuries and deaths on record involve accidents (falls, traffic, drowning) during this extended window, not the drug itself.
Psychological crisis. A "bad trip" can involve overwhelming fear, paranoia, or a terrifying loss of a stable sense of self, and can be genuinely traumatic without careful setting and support. In people with a personal or family history of psychosis or schizophrenia, LSD can trigger or unmask a serious psychotic episode — this is the single most important contraindication.
HPPD. A small minority of users develop Hallucinogen Persisting Perception Disorder — recurring visual disturbances (trails, halos, static in vision) that can persist long after the drug has left the body. It's uncommon but real and not fully predictable in advance.
Dose inconsistency. Because an active dose is so microscopically small, illicit blotter paper can vary significantly in strength between batches, making accidental overdose of the intended dose (not a toxic one, but a much more intense psychological experience than planned) a real practical risk.
Dangerous interactions. Combining LSD with lithium (a common medication for bipolar disorder) has been linked to seizures and is specifically flagged as dangerous by harm-reduction organizations; MAOIs and other psychiatric medications can also interact unpredictably.
LSD's physical safety profile is unusually good by drug standards. Its psychological safety profile depends almost entirely on who's taking it, in what state of mind, in what setting, and that's exactly the variable a legal ban can't control for.
The therapeutic case, and where it stands now
After decades of research shutdown, controlled clinical studies resumed in the 2000s. Current trials are investigating LSD for anxiety (particularly existential anxiety tied to serious illness), depression, and alcohol use disorder, generally using one or a few sessions combined with structured psychological support before and after — a fundamentally different model from daily medication. In 2026 an LSD-based drug (DT120, from Definium Therapeutics, formerly MindMed) reported three positive Phase 3 trials: one in major depression (June) and two in generalized anxiety disorder (August and September). In the Voyage anxiety trial, a single 100-microgram dose cut anxiety scores by 11.6 points at 12 weeks, against 6.2 on placebo. The company plans to apply for FDA approval in the first half of 2027, which puts it a step behind psilocybin, whose application is already under review (see the psilocybin piece). Microdosing (tiny, sub-perceptual doses) is a separate question: placebo-controlled studies so far, such as a 2021 self-blinding study in eLife, have mostly found effects no bigger than placebo. None of this is settled — regulatory review and real-world approval are still ahead — but the research base is now substantially more rigorous than anything available during the drug's first psychiatric era.
Try this
If you want to understand the actual scale of an LSD dose, look up a photo comparing a single grain of table salt to a typical 100-microgram dose of LSD — the visual is a fast, honest way to grasp both why so little produces such a large effect, and why dose consistency is such a real practical concern.
The takeaway
LSD was discovered by accident in 1943, used seriously in psychiatric research through the 1950s and '60s, then swept into Schedule I in 1970 largely for cultural and political reasons that shut down legitimate research for decades. It isn't physically addictive and has no documented direct-overdose deaths, but its real risks are psychological: a long, unpredictable trip, a genuine risk of triggering psychosis in vulnerable individuals, rare but real HPPD, and dangerous interactions with certain medications. Modern, more rigorous clinical trials are now investigating it for anxiety, depression, and alcohol use disorder, with positive Phase 3 results in 2026 and an FDA application planned for 2027.
Try this: look up a real-scale comparison image of an active LSD dose against a grain of salt to grasp just how small an active dose actually is.
Sources & Further Reading
Sources
- Hofmann's discovery and Bicycle Day reflect his own published account and standard chemical-history documentation.
- The 1950s–60s Canadian psychedelic-therapy research for alcoholism and its later Schedule I classification under the 1970 Controlled Substances Act reflect documented drug-policy history.
- HPPD, psychosis risk, lithium interaction warnings, and dose-consistency issues reflect published harm-reduction and clinical literature (e.g., from organizations including DanceSafe and the clinical psychiatric literature on hallucinogen persisting perception disorder).
- Clinical trial status: Definium Therapeutics press releases on the Phase 3 Voyage (12 August 2026) and Panorama (14 September 2026) results in generalized anxiety disorder, and its plan to file in the first half of 2027. Microdosing: Szigeti et al., "Self-blinding citizen science to explore psychedelic microdosing," eLife, 2021.
Go deeper
- 📘 LSD: My Problem Child — Albert Hofmann's own account of discovering and researching the drug
- 🌐 Search "Nutt 2010 Lancet LSD harm score" for how LSD compares to other drugs on the rigorous scale covered in this category's opening piece
- 🌐 DanceSafe.org — harm-reduction information, including drug interaction warnings
- 🌐 Related piece in this library: The Real Harm Ladder, this category